Therapy of endocrine disease: Treatment of malignant pheochromocytoma and paraganglioma

Eric Baudin; Mouhammed Amir Habra; Frederic Deschamps; Gilbert Cote; Frederic Dumont; Maria Cabanillas; J. Arfi-Roufe; A. Berdelou; Bryan Moon; Abir Al Ghuzlan; Shreyaskumar Patel; Sophie Leboulleux; Camilo Jimenez

doi:10.1530/EJE-14-0113

Therapy of endocrine disease: Treatment of malignant pheochromocytoma and paraganglioma

Eric Baudin, Mouhammed Amir Habra, Frederic Deschamps, Gilbert Cote, Frederic Dumont, Maria Cabanillas, J. Arfi-Roufe, A. Berdelou, Bryan Moon, Abir Al Ghuzlan, Shreyaskumar Patel, Sophie Leboulleux, Camilo Jimenez

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

88 Citations (Scopus)

Résumé

Metastatic pheochromocytomas and paragangliomas (MPPs) present clinicianswith three major challenges: scarcity, complexity of characterization, and heterogeneous behavior and prognosis. As with the treatment for all neuroendocrine tumors, the control of hormonal symptoms and tumor growth is the main therapeutic objective in MPP patients. A significant number of MPP patients still die from uncontrolled hormone secretion. In addition, the management of MPPs remains palliative. Steps forward include proper characterization of MPP patients at large cancer referral centerswithmultidisciplinary teams; improved strategies to stratify patients prognostically; and implementation of trials within national and international networks. Progress in the molecular characterization and staging of MPPs constitutes the basis for significant treatment breakthroughs.

langue originale	Anglais
Pages (de - à)	R111-R122
journal	European Journal of Endocrinology
Volume	171
Numéro de publication	3
Les DOIs	https://doi.org/10.1530/EJE-14-0113
état	Publié - 1 sept. 2014

Accès au document

10.1530/EJE-14-0113

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{83d3fd77eab94aada5bfcbdb66280882,

title = "Therapy of endocrine disease: Treatment of malignant pheochromocytoma and paraganglioma",

abstract = "Metastatic pheochromocytomas and paragangliomas (MPPs) present clinicianswith three major challenges: scarcity, complexity of characterization, and heterogeneous behavior and prognosis. As with the treatment for all neuroendocrine tumors, the control of hormonal symptoms and tumor growth is the main therapeutic objective in MPP patients. A significant number of MPP patients still die from uncontrolled hormone secretion. In addition, the management of MPPs remains palliative. Steps forward include proper characterization of MPP patients at large cancer referral centerswithmultidisciplinary teams; improved strategies to stratify patients prognostically; and implementation of trials within national and international networks. Progress in the molecular characterization and staging of MPPs constitutes the basis for significant treatment breakthroughs.",

author = "Eric Baudin and Habra, {Mouhammed Amir} and Frederic Deschamps and Gilbert Cote and Frederic Dumont and Maria Cabanillas and J. Arfi-Roufe and A. Berdelou and Bryan Moon and Ghuzlan, {Abir Al} and Shreyaskumar Patel and Sophie Leboulleux and Camilo Jimenez",

note = "Publisher Copyright: {\textcopyright} 2014 European Society of Endocrinology Printed in Great Britain.",

year = "2014",

month = sep,

day = "1",

doi = "10.1530/EJE-14-0113",

language = "English",

volume = "171",

pages = "R111--R122",

journal = "European Journal of Endocrinology",

issn = "0804-4643",

number = "3",

}

TY - JOUR

T1 - Therapy of endocrine disease

T2 - Treatment of malignant pheochromocytoma and paraganglioma

AU - Baudin, Eric

AU - Habra, Mouhammed Amir

AU - Deschamps, Frederic

AU - Cote, Gilbert

AU - Dumont, Frederic

AU - Cabanillas, Maria

AU - Arfi-Roufe, J.

AU - Berdelou, A.

AU - Moon, Bryan

AU - Ghuzlan, Abir Al

AU - Patel, Shreyaskumar

AU - Leboulleux, Sophie

AU - Jimenez, Camilo

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Metastatic pheochromocytomas and paragangliomas (MPPs) present clinicianswith three major challenges: scarcity, complexity of characterization, and heterogeneous behavior and prognosis. As with the treatment for all neuroendocrine tumors, the control of hormonal symptoms and tumor growth is the main therapeutic objective in MPP patients. A significant number of MPP patients still die from uncontrolled hormone secretion. In addition, the management of MPPs remains palliative. Steps forward include proper characterization of MPP patients at large cancer referral centerswithmultidisciplinary teams; improved strategies to stratify patients prognostically; and implementation of trials within national and international networks. Progress in the molecular characterization and staging of MPPs constitutes the basis for significant treatment breakthroughs.

AB - Metastatic pheochromocytomas and paragangliomas (MPPs) present clinicianswith three major challenges: scarcity, complexity of characterization, and heterogeneous behavior and prognosis. As with the treatment for all neuroendocrine tumors, the control of hormonal symptoms and tumor growth is the main therapeutic objective in MPP patients. A significant number of MPP patients still die from uncontrolled hormone secretion. In addition, the management of MPPs remains palliative. Steps forward include proper characterization of MPP patients at large cancer referral centerswithmultidisciplinary teams; improved strategies to stratify patients prognostically; and implementation of trials within national and international networks. Progress in the molecular characterization and staging of MPPs constitutes the basis for significant treatment breakthroughs.

UR - http://www.scopus.com/inward/record.url?scp=84907220377&partnerID=8YFLogxK

U2 - 10.1530/EJE-14-0113

DO - 10.1530/EJE-14-0113

M3 - Review article

C2 - 24891137

AN - SCOPUS:84907220377

SN - 0804-4643

VL - 171

SP - R111-R122

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

IS - 3

ER -